LIVIVO - The Search Portal for Life Sciences

zur deutschen Oberfläche wechseln
Advanced search

Search results

Result 1 - 10 of total 22

Search options

  1. Article ; Online: A Versatile Protocol to Quantify BCR-mediated Phosphorylation in Human and Murine B Cell Subpopulations.

    Rip, Jasper / Hendriks, Rudi W / Corneth, Odilia B J

    Bio-protocol

    2021  Volume 11, Issue 3, Page(s) e3902

    Abstract: Signal transduction is the process by which molecular signals are transmitted from the cell surface to its interior, resulting in functional changes inside the cell. B cell receptor (BCR) signaling is of crucial importance for B cells, as it regulates ... ...

    Abstract Signal transduction is the process by which molecular signals are transmitted from the cell surface to its interior, resulting in functional changes inside the cell. B cell receptor (BCR) signaling is of crucial importance for B cells, as it regulates their differentiation, selection, survival, cellular activation and proliferation. Upon BCR engagement by antigen several protein kinases, lipases and linker molecules become phosphorylated. Phosphoflow cytometry (phosphoflow) is a flow cytometry-based method allowing for analysis of protein phosphorylation in single cells. Due to recent advances in methodology and antibody availability - together with the relatively easy quantification of phosphorylation - phosphoflow is increasingly and more commonly used, compared to classical western blot analysis. It can however be challenging to set-up a method that works for all targets of interest. Here, we present a step-by-step phosphoflow protocol allowing the evaluation of the phosphorylation status of signaling molecules in conjunction with extensive staining to identify various human and murine B cell subpopulations, as was previously published in the original paper by Rip
    Language English
    Publishing date 2021-02-05
    Publishing country United States
    Document type Journal Article
    ZDB-ID 2833269-6
    ISSN 2331-8325 ; 2331-8325
    ISSN (online) 2331-8325
    ISSN 2331-8325
    DOI 10.21769/BioProtoc.3902
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  2. Article ; Online: Epstein-Barr virus and genetic risk variants as determinants of T-bet

    Bogers, Laurens / Kuiper, Kirsten L / Smolders, Joost / Rip, Jasper / van Luijn, Marvin M

    Immunology letters

    2023  Volume 261, Page(s) 66–74

    Abstract: B cells expressing the transcription factor T-bet are found to have a protective role in viral infections, but are also considered major players in the onset of different types of autoimmune diseases. Currently, the exact mechanisms driving such ' ... ...

    Abstract B cells expressing the transcription factor T-bet are found to have a protective role in viral infections, but are also considered major players in the onset of different types of autoimmune diseases. Currently, the exact mechanisms driving such 'atypical' memory B cells to contribute to protective immunity or autoimmunity are unclear. In addition to general autoimmune-related factors including sex and age, the ways T-bet
    MeSH term(s) Humans ; Herpesvirus 4, Human/genetics ; Epstein-Barr Virus Infections ; Autoimmune Diseases ; Risk Factors ; Lupus Erythematosus, Systemic
    Language English
    Publishing date 2023-07-13
    Publishing country Netherlands
    Document type Journal Article ; Research Support, Non-U.S. Gov't
    ZDB-ID 445150-8
    ISSN 1879-0542 ; 0165-2478
    ISSN (online) 1879-0542
    ISSN 0165-2478
    DOI 10.1016/j.imlet.2023.07.006
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  3. Article ; Online: Ocrelizumab associates with reduced cerebrospinal fluid B and CD20

    van Puijfelik, Fabiënne / Blok, Katelijn M / Klein Kranenbarg, Romy A M / Rip, Jasper / de Beukelaar, Janet / Wierenga-Wolf, Annet F / Wokke, Beatrijs / van Luijn, Marvin M / Smolders, Joost

    Brain communications

    2024  Volume 6, Issue 1, Page(s) fcae021

    Abstract: The anti-CD20 monoclonal antibody ocrelizumab reduces disability progression in primary progressive multiple sclerosis. CD20 is a prototypical B-cell marker; however, subpopulations of ... ...

    Abstract The anti-CD20 monoclonal antibody ocrelizumab reduces disability progression in primary progressive multiple sclerosis. CD20 is a prototypical B-cell marker; however, subpopulations of CD4
    Language English
    Publishing date 2024-01-29
    Publishing country England
    Document type Journal Article
    ISSN 2632-1297
    ISSN (online) 2632-1297
    DOI 10.1093/braincomms/fcae021
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  4. Article ; Online: Bruton's Tyrosine Kinase Inhibition as an Emerging Therapy in Systemic Autoimmune Disease.

    Neys, Stefan F H / Rip, Jasper / Hendriks, Rudi W / Corneth, Odilia B J

    Drugs

    2021  Volume 81, Issue 14, Page(s) 1605–1626

    Abstract: Systemic autoimmune disorders are complex heterogeneous chronic diseases involving many different immune cells. A significant proportion of patients respond poorly to therapy. In addition, the high burden of adverse effects caused by "classical" anti- ... ...

    Abstract Systemic autoimmune disorders are complex heterogeneous chronic diseases involving many different immune cells. A significant proportion of patients respond poorly to therapy. In addition, the high burden of adverse effects caused by "classical" anti-rheumatic or immune modulatory drugs provides a need to develop more specific therapies that are better tolerated. Bruton's tyrosine kinase (BTK) is a crucial signaling protein that directly links B-cell receptor (BCR) signals to B-cell activation, proliferation, and survival. BTK is not only expressed in B cells but also in myeloid cells, and is involved in many different signaling pathways that drive autoimmunity. This makes BTK an interesting therapeutic target in the treatment of autoimmune diseases. The past decade has seen the emergence of first-line BTK small-molecule inhibitors with great efficacy in the treatment of B-cell malignancies, but with unfavorable safety profiles for use in autoimmunity due to off-target effects. The development of second-generation BTK inhibitors with superior BTK specificity has facilitated the investigation of their efficacy in clinical trials with autoimmune patients. In this review, we discuss the role of BTK in key signaling pathways involved in autoimmunity and provide an overview of the different inhibitors that are currently being investigated in clinical trials of systemic autoimmune diseases, including rheumatoid arthritis and systemic lupus erythematosus, as well as available results from completed trials.
    MeSH term(s) Agammaglobulinaemia Tyrosine Kinase/antagonists & inhibitors ; Autoimmune Diseases/drug therapy ; Autoimmunity/drug effects ; B-Lymphocytes/drug effects ; Clinical Trials as Topic ; Humans ; Lymphocyte Activation/drug effects ; Receptors, Antigen, B-Cell/metabolism ; Signal Transduction/drug effects
    Chemical Substances Receptors, Antigen, B-Cell ; Agammaglobulinaemia Tyrosine Kinase (EC 2.7.10.2)
    Language English
    Publishing date 2021-10-05
    Publishing country New Zealand
    Document type Journal Article ; Review
    ZDB-ID 120316-2
    ISSN 1179-1950 ; 0012-6667
    ISSN (online) 1179-1950
    ISSN 0012-6667
    DOI 10.1007/s40265-021-01592-0
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  5. Article ; Online: Phosphoflow Protocol for Signaling Studies in Human and Murine B Cell Subpopulations.

    Rip, Jasper / de Bruijn, Marjolein J W / Kaptein, Allard / Hendriks, Rudi W / Corneth, Odilia B J

    Journal of immunology (Baltimore, Md. : 1950)

    2020  Volume 204, Issue 10, Page(s) 2852–2863

    Abstract: BCR signaling, involving phosphorylation of various downstream molecules, including kinases, lipases, and linkers, is crucial for B cell selection, survival, proliferation, and differentiation. Phosphoflow cytometry (phosphoflow) is a single-cell-based ... ...

    Abstract BCR signaling, involving phosphorylation of various downstream molecules, including kinases, lipases, and linkers, is crucial for B cell selection, survival, proliferation, and differentiation. Phosphoflow cytometry (phosphoflow) is a single-cell-based technique to measure phosphorylated intracellular proteins, providing a more quantitative read-out than Western blotting. Recent advances in phosphoflow basically allow simultaneous analysis of protein phosphorylation in B cell (sub)populations, without prior cell sorting. However, fixation and permeabilization procedures required for phosphoflow often affect cell surface epitopes or mAb conjugates, precluding the evaluation of the phosphorylation status of signaling proteins across different B cell subpopulations present in a single sample. In this study, we report a versatile phosphoflow protocol allowing extensive staining of B cell subpopulations in human peripheral blood or various anatomical compartments in the mouse, starting from freshly isolated or frozen cell suspensions. Both human and mouse B cell subpopulations showed different basal and BCR stimulation-induced phosphorylation levels of downstream signaling proteins. For example, peritoneal B-1 cells and splenic marginal zone B cells exhibited significantly increased basal (ex vivo) signaling and increased responsiveness to in vitro BCR stimulation compared with peritoneal B-2 cells and splenic follicular B cells, respectively. In addition, whereas stimulation with anti-IgM or anti-Igκ L chain Abs resulted in strong pCD79a and pPLCγ2 signals, IgD stimulation only induced CD79a but not pPLCγ2 phosphorylation. In summary, the protocol is user friendly and quantifies BCR-mediated phosphorylation with high sensitivity at the single-cell level, in combination with extensive staining to identify individual B cell development and differentiation stages.
    MeSH term(s) Animals ; B-Lymphocyte Subsets/physiology ; B-Lymphocytes/physiology ; CD79 Antigens/metabolism ; Cell Differentiation ; Cells, Cultured ; Flow Cytometry/methods ; Humans ; Immunoglobulin D/metabolism ; Immunoglobulin M/metabolism ; Lymphocyte Activation ; Mice ; Mice, Inbred C57BL ; Phospholipase C gamma/metabolism ; Phosphorylation ; Receptors, Antigen, B-Cell/metabolism ; Signal Transduction ; Single-Cell Analysis
    Chemical Substances CD79 Antigens ; Immunoglobulin D ; Immunoglobulin M ; Receptors, Antigen, B-Cell ; PLCG2 protein, human (EC 3.1.4.3) ; Phospholipase C gamma (EC 3.1.4.3)
    Language English
    Publishing date 2020-04-06
    Publishing country United States
    Document type Journal Article ; Research Support, Non-U.S. Gov't
    ZDB-ID 3056-9
    ISSN 1550-6606 ; 0022-1767 ; 1048-3233 ; 1047-7381
    ISSN (online) 1550-6606
    ISSN 0022-1767 ; 1048-3233 ; 1047-7381
    DOI 10.4049/jimmunol.1901117
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  6. Article ; Online: Differential Runx3, Eomes, and T-bet expression subdivides MS-associated CD4

    Hoeks, Cindy / Puijfelik, Fabiënne van / Koetzier, Steven C / Rip, Jasper / Corsten, Cato E A / Wierenga-Wolf, Annet F / Melief, Marie-José / Stinissen, Piet / Smolders, Joost / Hellings, Niels / Broux, Bieke / van Luijn, Marvin M

    European journal of immunology

    2023  Volume 54, Issue 2, Page(s) e2350544

    Abstract: Multiple sclerosis (MS) is a common and devastating chronic inflammatory disease of the CNS. ... ...

    Abstract Multiple sclerosis (MS) is a common and devastating chronic inflammatory disease of the CNS. CD4
    MeSH term(s) Humans ; Brain/pathology ; CD28 Antigens/metabolism ; CD4-Positive T-Lymphocytes/metabolism ; Core Binding Factor Alpha 3 Subunit/metabolism ; Granzymes/metabolism ; Multiple Sclerosis/genetics
    Chemical Substances CD28 Antigens ; Core Binding Factor Alpha 3 Subunit ; Granzymes (EC 3.4.21.-) ; Runx3 protein, human ; T-box transcription factor TBX21
    Language English
    Publishing date 2023-12-07
    Publishing country Germany
    Document type Journal Article
    ZDB-ID 120108-6
    ISSN 1521-4141 ; 0014-2980
    ISSN (online) 1521-4141
    ISSN 0014-2980
    DOI 10.1002/eji.202350544
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  7. Article ; Online: Aberrant B Cell Receptor Signaling in Naïve B Cells from Patients with Idiopathic Pulmonary Fibrosis.

    Neys, Stefan F H / Heukels, Peter / van Hulst, Jennifer A C / Rip, Jasper / Wijsenbeek, Marlies S / Hendriks, Rudi W / Corneth, Odilia B J

    Cells

    2021  Volume 10, Issue 6

    Abstract: Idiopathic pulmonary fibrosis (IPF) is a chronic and ultimately fatal disease in which an impaired healing response to recurrent micro-injuries is thought to lead to fibrosis. Recent findings hint at a role for B cells and autoimmunity in IPF ... ...

    Abstract Idiopathic pulmonary fibrosis (IPF) is a chronic and ultimately fatal disease in which an impaired healing response to recurrent micro-injuries is thought to lead to fibrosis. Recent findings hint at a role for B cells and autoimmunity in IPF pathogenesis. We previously reported that circulating B cells from a fraction of patients, compared with healthy controls, express increased levels of the signaling molecule Bruton's tyrosine kinase (BTK). However, it remains unclear whether B cell receptor (BCR) signaling is altered in IPF. Here, we show that the response to BCR stimulation is enhanced in peripheral blood B cells from treatment-naïve IPF patients. We observed increased anti-immunoglobulin-induced phosphorylation of BTK and its substrate phospholipase Cγ2 (PLCγ2) in naïve but not in memory B cells of patients with IPF. In naïve B cells of IPF patients enhanced BCR signaling correlated with surface expression of transmembrane activator and calcium-modulator and cyclophilin ligand interactor (TACI) but not B cell activating factor receptor (BAFFR), both of which provide pro-survival signals. Interestingly, treatment of IPF patients with nintedanib, a tyrosine kinase inhibitor with anti-fibrotic and anti-inflammatory activity, induced substantial changes in BCR signaling. These findings support the involvement of B cells in IPF pathogenesis and suggest that targeting BCR signaling has potential value as a treatment option.
    MeSH term(s) Agammaglobulinaemia Tyrosine Kinase/drug effects ; Agammaglobulinaemia Tyrosine Kinase/metabolism ; Arthritis, Rheumatoid/metabolism ; B-Lymphocytes/drug effects ; B-Lymphocytes/immunology ; Humans ; Idiopathic Pulmonary Fibrosis/drug therapy ; Lymphocyte Activation/drug effects ; Phospholipase C gamma/metabolism ; Protein Kinase Inhibitors/pharmacology ; Protein-Tyrosine Kinases/drug effects ; Protein-Tyrosine Kinases/metabolism
    Chemical Substances Protein Kinase Inhibitors ; Protein-Tyrosine Kinases (EC 2.7.10.1) ; Agammaglobulinaemia Tyrosine Kinase (EC 2.7.10.2) ; Phospholipase C gamma (EC 3.1.4.3)
    Language English
    Publishing date 2021-05-26
    Publishing country Switzerland
    Document type Journal Article ; Research Support, Non-U.S. Gov't
    ZDB-ID 2661518-6
    ISSN 2073-4409 ; 2073-4409
    ISSN (online) 2073-4409
    ISSN 2073-4409
    DOI 10.3390/cells10061321
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  8. Article ; Online: Splenic Architecture and Function Requires Tight Control of Transmembrane TNF Expression.

    Jeucken, Kim C M / Kaaij, Merlijn H / Rip, Jasper / van Rooijen, Charlotte C N / Kan, Yik Y / Corneth, Odilia B J / van Hamburg, Jan Piet / Tas, Sander W

    International journal of molecular sciences

    2022  Volume 23, Issue 4

    Abstract: Soluble tumor necrosis factor (sTNF) is an important inflammatory mediator and essential for secondary lymphoid organ (SLO) development and function. However, the role of its transmembrane counterpart (tmTNF) in these processes is less well established. ... ...

    Abstract Soluble tumor necrosis factor (sTNF) is an important inflammatory mediator and essential for secondary lymphoid organ (SLO) development and function. However, the role of its transmembrane counterpart (tmTNF) in these processes is less well established. Here, the effects of tmTNF overxpression on SLO architecture and function were investigated using tmTNF-transgenic (tmTNF-tg) mice. tmTNF overexpression resulted in enlarged peripheral lymph nodes (PLNs) and spleen, accompanied by an increase in small splenic lymphoid follicles, with less well-defined primary B cell follicles and T cell zones. In tmTNF-tg mice, the spleen, but not PLNs, contained reduced germinal center (GC) B cell fractions, with low Ki67 expression and reduced dark zone characteristics. In line with this, smaller fractions of T follicular helper (Tfh) and T follicular regulatory (Tfr) cells were observed with a decreased Tfh:Tfr ratio. Moreover, plasma cell (PC) formation in the spleen of tmTNF-tg mice decreased and skewed towards IgA and IgM expression. Genetic deletion of TNFRI or -II resulted in a normalization of follicle morphology in the spleen of tmTNF-tg mice, but GC B cell and PC fractions remained abnormal. These findings demonstrate that tightly regulated tmTNF is important for proper SLO development and function, and that aberrations induced by tmTNF overexpression are site-specific and mediated via TNFRI and/or TNFRII signaling.
    MeSH term(s) Animals ; B-Lymphocytes/metabolism ; Germinal Center/metabolism ; Immunoglobulin A/metabolism ; Immunoglobulin M/metabolism ; Mice ; Mice, Inbred C57BL ; Mice, Transgenic ; Plasma Cells/metabolism ; Receptors, Tumor Necrosis Factor, Type I/metabolism ; Receptors, Tumor Necrosis Factor, Type II/metabolism ; Signal Transduction/physiology ; Spleen/metabolism ; T Follicular Helper Cells/metabolism ; T-Lymphocytes, Regulatory/metabolism
    Chemical Substances Immunoglobulin A ; Immunoglobulin M ; Receptors, Tumor Necrosis Factor, Type I ; Receptors, Tumor Necrosis Factor, Type II
    Language English
    Publishing date 2022-02-17
    Publishing country Switzerland
    Document type Journal Article
    ZDB-ID 2019364-6
    ISSN 1422-0067 ; 1422-0067 ; 1661-6596
    ISSN (online) 1422-0067
    ISSN 1422-0067 ; 1661-6596
    DOI 10.3390/ijms23042229
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  9. Article: The Role of Bruton's Tyrosine Kinase in Immune Cell Signaling and Systemic Autoimmunity.

    Rip, Jasper / Van Der Ploeg, Esmee K / Hendriks, Rudi W / Corneth, Odilia B J

    Critical reviews in immunology

    2018  Volume 38, Issue 1, Page(s) 17–62

    Abstract: Bruton's tyrosine kinase (BTK) is an intracellular signaling molecule first identified as the molecule affected in X-linked agammaglobulinemia (XLA) patients, who almost completely lack peripheral B cells and serum immunoglobulins. BTK is crucial for B ... ...

    Abstract Bruton's tyrosine kinase (BTK) is an intracellular signaling molecule first identified as the molecule affected in X-linked agammaglobulinemia (XLA) patients, who almost completely lack peripheral B cells and serum immunoglobulins. BTK is crucial for B cell development and various B cell functions, including cytokine and natural antibody production. Importantly, it is also expressed in numerous other cells, including monocytes, macrophages, granulocytes, dendritic cells, and osteoclasts. A few rare cases of autoimmune disease in XLA patients have been described. Interestingly, increased BTK protein expression in patients with systemic autoimmune disease appears to be correlated with autoantibody production. In addition, BTK may promote autoimmunity as an important driver of an imbalance in B-T cell interaction. Because of this overwhelming evidence of a pathogenic role of BTK in autoimmunity, several clinical trials in rheumatoid arthritis and systemic lupus erythematosus patients with BTK inhibitors are currently running. Here, we review BTK function in different signaling pathways and in different cell lineages, focusing on the growing body of literature indicating a critical role for BTK in autoimmunity. We also discuss BTK and the promising results of BTK inhibition in animal models of autoimmune disease.
    MeSH term(s) Agammaglobulinaemia Tyrosine Kinase/antagonists & inhibitors ; Agammaglobulinaemia Tyrosine Kinase/immunology ; Agammaglobulinaemia Tyrosine Kinase/metabolism ; Animals ; Autoimmune Diseases/drug therapy ; Autoimmune Diseases/immunology ; Autoimmune Diseases/metabolism ; Autoimmunity/immunology ; Humans ; Protein Kinase Inhibitors/pharmacology ; Signal Transduction
    Chemical Substances Protein Kinase Inhibitors ; Agammaglobulinaemia Tyrosine Kinase (EC 2.7.10.2)
    Language English
    Publishing date 2018-06-07
    Publishing country United States
    Document type Journal Article ; Research Support, Non-U.S. Gov't ; Review
    ZDB-ID 1353116-5
    ISSN 1040-8401
    ISSN 1040-8401
    DOI 10.1615/CritRevImmunol.2018025184
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  10. Article ; Online: Human T-bet+ B cell development is associated with BTK activity and suppressed by evobrutinib.

    Rijvers, Liza / van Langelaar, Jamie / Bogers, Laurens / Melief, Marie-José / Koetzier, Steven C / Blok, Katelijn M / Wierenga-Wolf, Annet F / de Vries, Helga E / Rip, Jasper / Corneth, Odilia Bj / Hendriks, Rudi W / Grenningloh, Roland / Boschert, Ursula / Smolders, Joost / van Luijn, Marvin M

    JCI insight

    2022  Volume 7, Issue 16

    Abstract: Recent clinical trials have shown promising results for the next-generation Bruton's tyrosine kinase (BTK) inhibitor evobrutinib in the treatment of multiple sclerosis (MS). BTK has a central role in signaling pathways that govern the development of B ... ...

    Abstract Recent clinical trials have shown promising results for the next-generation Bruton's tyrosine kinase (BTK) inhibitor evobrutinib in the treatment of multiple sclerosis (MS). BTK has a central role in signaling pathways that govern the development of B cells. Whether and how BTK activity shapes B cells as key drivers of MS is currently unclear. Compared with levels of BTK protein, we found higher levels of phospho-BTK in ex vivo blood memory B cells from patients with relapsing-remitting MS and secondary progressive MS compared with controls. In these MS groups, BTK activity was induced to a lesser extent after anti-IgM stimulation. BTK positively correlated with CXCR3 expression, both of which were increased in blood B cells from clinical responders to natalizumab (anti-VLA-4 antibody) treatment. Under in vitro T follicular helper-like conditions, BTK phosphorylation was enhanced by T-bet-inducing stimuli, IFN-γ and CpG-ODN, while the expression of T-bet and T-bet-associated molecules CXCR3, CD21, and CD11c was affected by evobrutinib. Furthermore, evobrutinib interfered with in vitro class switching, as well as memory recall responses, and disturbed CXCL10-mediated migration of CXCR3+ switched B cells through human brain endothelial monolayers. These findings demonstrate a functional link between BTK activity and disease-relevant B cells and offer valuable insights into how next-generation BTK inhibitors could modulate the clinical course of patients with MS.
    MeSH term(s) Agammaglobulinaemia Tyrosine Kinase ; Humans ; Multiple Sclerosis/drug therapy ; Phosphorylation ; Piperidines ; Pyrimidines/pharmacology ; Pyrimidines/therapeutic use ; T-Box Domain Proteins/metabolism
    Chemical Substances Piperidines ; Pyrimidines ; T-Box Domain Proteins ; Agammaglobulinaemia Tyrosine Kinase (EC 2.7.10.2) ; evobrutinib (ZA45457L1K)
    Language English
    Publishing date 2022-08-22
    Publishing country United States
    Document type Journal Article ; Research Support, Non-U.S. Gov't
    ISSN 2379-3708
    ISSN (online) 2379-3708
    DOI 10.1172/jci.insight.160909
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

To top